CoChat

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

Open access
Sheng, Hailong, Huang, Yan, Xiao, Yazhi, Zhu, Zhenru, Shen, Mengying, Zhou, Peitao, Guo, Zeqin, Wang, Jian, Wang, Hui, Dai, Wencong, Zhang, Wanjun, Sun, Jingyuan, Cao, Chuanhui · 2020 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Background Radioimmunotherapy has a promising antitumor effect in hepatocellular carcinoma (HCC), depending on the regulatory effect of radiotherapy on tumor immune microenvironment. Ionizing radiation (IR)-induced DNA damage repair (DDR) pathway activation leads to the inhibition of immune microenvironment, thus impairing the antitumor effect of radioimmunotherapy. However, it is unclear whether inhibition of the DDR pathway can enhance the effect of radioimmunotherapy. In this study, we aim to explore the role of DDR inhibitor AZD6738 on the combination of radiotherapy and immune checkpoint inhibitors (ICIs) in HCC. Methods C57BL/6 mouse subcutaneous tumor model was used to evaluate the ability of different treatment regimens in tumor growth control and tumor recurrence inhibition. Effects of each treatment regimen on the alterations of immunophenotypes including the quantification, activation, proliferating ability, exhaustion marker expression, and memory status were assessed by flow cytometry. Results AZD6738 further increased radiotherapy-stimulated CD8 + T cell infiltration and activation and reverted the immunosuppressive effect of radiation on the number of Tregs in mice xenografts. Moreover, compared with radioimmunotherapy (radiotherapy plus anti-PD-L1 (Programmed death ligand 1)), the addition of AZD6738 boosted the infiltration, increased cell proliferation, enhanced interferon (IFN)-γ production ability of TIL (tumor-infiltrating lymphocyte) CD8 + T cells, and caused a decreasing trend in the number of TIL Tregs and exhausted T cells in mice xenografts. Thus, the tumor immune microenvironment was significantly improved. Meanwhile, triple therapy (AZD6738 plus radiotherapy plus anti-PD-L1) also induced a better immunophenotype than radioimmunotherapy in mice spleens. As a consequence, triple therapy displayed greater benefit in antitumor efficacy and mice survival than radioimmunotherapy. Mechanism study revealed that the synergistic antitumor effect of AZD6738 with radioimmunotherapy relied on the activation of cyclic GMP–AMP synthase /stimulator of interferon genes (cGAS/STING) signaling pathway. Furthermore, triple therapy led to stronger immunologic memory and lasting antitumor immunity than radioimmunotherapy, thus preventing tumor recurrence in mouse models. Conclusions Our findings indicate that AZD6738 might be a potential synergistic treatment for radioimmunotherapy to control the proliferation of HCC cells, prolong survival, and prevent tumor recurrence in patients with HCC by improving the immune microenvironment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2019-000340

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 AZD6738 improves immune microenvironment in mice hepatocellular carcinoma (HCC) tissues after radiotherapy. (A) Representative contour plots depicting the percentages of tumor-infiltrating (TIL) Tregs (CD25+Foxp3+), and the quantitation of the number of TIL Tregs per 104 cells stained at days 8 and 14 was shown. (B) Representative contour plots and quantification of CD8+/CD3+ ratios at days 8 and 14. (C) Quantitation of PD-1 and Tim3 median fluorescence intensity in TIL CD8+ T cells at days 8 and 14. (D) Representative contour plots and quantification of the percentage of TIL PD-1+ CD8+ T cells at days 8 and 14. (E) Representative contour plots and quantification of TIL CD8+ T cells that elicit IFN-γ following stimulation with PMA/ionomycin at days 8 and 14. Data represent the mean±SD for (A)-(E), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005;+ ****p<0.0001. IFN-γ, interferon-γ; IR, ionizing radiation; PMA, phorbol 12-myristate 13-acetate.
Figure 1 AZD6738 improves immune microenvironment in mice hepatocellular carcinoma (HCC) tissues after radiotherapy. (A) Representative contour plots depicting the percentages of tumor-infiltrating (TIL) Tregs (CD25+Foxp3+), and the quantitation of the number of TIL Tregs per 104 cells stained at days 8 and 14 was shown. (B) Representative contour plots and quantification of CD8+/CD3+ ratios at days 8 and 14. (C) Quantitation of PD-1 and Tim3 median fluorescence intensity in TIL CD8+ T cells at days 8 and 14. (D) Representative contour plots and quantification of the percentage of TIL PD-1+ CD8+ T cells at days 8 and 14. (E) Representative contour plots and quantification of TIL CD8+ T cells that elicit IFN-γ following stimulation with PMA/ionomycin at days 8 and 14. Data represent the mean±SD for (A)-(E), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005;+ ****p<0.0001. IFN-γ, interferon-γ; IR, ionizing radiation; PMA, phorbol 12-myristate 13-acetate.CC BY · PubMed Central
Figure 2 Addition of AZD6738 potentiates radiation combined with anti-PD-L1 therapy in mice tumor growth control and survival improvement. (A) Schematic showing schedules of ionizing radiation (IR), AZD6738, and anti-PD-L1 treatment. (B–C) Response of the subcutaneous tumors (B) or individual tumor volumes (C) to the indicated treatment regimens. n=12 in each group. Data represent the mean±SEM. (D) Survival plots for each treatment regimens were shown. (E) Response of the orthotopic hepatocellular carcinoma (HCC) tumors to treatment with the indicated treatment regimens. n=5 in each group. Data represent the mean±SEM. (F) Representative images of mice liver MRI before treatment and the corresponded isolated liver samples after treatment. For (B), statistical analyses were performed using a mixed-effects model, followed by Tukey’s multiple comparison test. For (D), survival data were compared using the log-rank Mantel-Cox test. For (E), statistical analyses were performed using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; ***p<0.0005.
Figure 2 Addition of AZD6738 potentiates radiation combined with anti-PD-L1 therapy in mice tumor growth control and survival improvement. (A) Schematic showing schedules of ionizing radiation (IR), AZD6738, and anti-PD-L1 treatment. (B–C) Response of the subcutaneous tumors (B) or individual tumor volumes (C) to the indicated treatment regimens. n=12 in each group. Data represent the mean±SEM. (D) Survival plots for each treatment regimens were shown. (E) Response of the orthotopic hepatocellular carcinoma (HCC) tumors to treatment with the indicated treatment regimens. n=5 in each group. Data represent the mean±SEM. (F) Representative images of mice liver MRI before treatment and the corresponded isolated liver samples after treatment. For (B), statistical analyses were performed using a mixed-effects model, followed by Tukey’s multiple comparison test. For (D), survival data were compared using the log-rank Mantel-Cox test. For (E), statistical analyses were performed using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; ***p<0.0005.CC BY · PubMed Central
Figure 3 Triple therapy impacts T cell infiltration in mice tumors and spleen. (A) Schematic shows schedules of triple therapy including ionizing radiation (IR), AZD6738, and anti-PD-L1. The red frames indicated the time points for lymphocyte analyses in mice tumors or spleens. (B) Quantitation of the number of tumor-infiltrating lymphocyte (TIL) CD8+ T cells per 104 cells at days 8 and 14. (C) Quantitation of CD8+/CD3+ ratios in mice tumors. (D) Quantitation of the number of TIL Tregs per 104 cells. (E) Quantitation of CD8+/Treg ratios in mice tumors. (F) Quantitation of CD8+/Treg ratios in mice spleens. Data represent the mean±SD. For (B)–(F), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001.
Figure 3 Triple therapy impacts T cell infiltration in mice tumors and spleen. (A) Schematic shows schedules of triple therapy including ionizing radiation (IR), AZD6738, and anti-PD-L1. The red frames indicated the time points for lymphocyte analyses in mice tumors or spleens. (B) Quantitation of the number of tumor-infiltrating lymphocyte (TIL) CD8+ T cells per 104 cells at days 8 and 14. (C) Quantitation of CD8+/CD3+ ratios in mice tumors. (D) Quantitation of the number of TIL Tregs per 104 cells. (E) Quantitation of CD8+/Treg ratios in mice tumors. (F) Quantitation of CD8+/Treg ratios in mice spleens. Data represent the mean±SD. For (B)–(F), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001.CC BY · PubMed Central
Figure 4 Triple therapy promotes the proliferation of splenic and tumor-infiltrating T cells. (A–B) Representative contour plots of Ki67+ expression on tumor-infiltrating lymphocyte (TIL) and splenic CD8+ T cells at day 8. (C–D) Quantitation of the percentages of proliferating (Ki67+) TIL CD8+ T cells (C) and TIL CD4+ T cells (D) at days 8 and 14. (E–F) Quantitation of the percentages of proliferating (Ki67+) splenic CD8+ T cells (E) and splenic CD4+ T cells (F) at days 8 and 14. Data represent the mean±SD. For (C)–(F), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001. IR, ionizing radiation.
Figure 4 Triple therapy promotes the proliferation of splenic and tumor-infiltrating T cells. (A–B) Representative contour plots of Ki67+ expression on tumor-infiltrating lymphocyte (TIL) and splenic CD8+ T cells at day 8. (C–D) Quantitation of the percentages of proliferating (Ki67+) TIL CD8+ T cells (C) and TIL CD4+ T cells (D) at days 8 and 14. (E–F) Quantitation of the percentages of proliferating (Ki67+) splenic CD8+ T cells (E) and splenic CD4+ T cells (F) at days 8 and 14. Data represent the mean±SD. For (C)–(F), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001. IR, ionizing radiation.CC BY · PubMed Central
Figure 5 Triple therapy attenuates coexpression of CD8+ T cell exhaustion markers and promotes CD8+ T cell effector function in mice tumors. (A–B) Representative contour plots depicting PD-1 and LAG-3 coexpression and PD-1 and Tim-3 coexpression on tumor-infiltrating lymphocyte (TIL) CD8+ T cells at day 8. (C–D) Quantitation of the percentage of TIL CD8+ T cells coexpressing PD-1 and LAG-3 (C), and PD-1 and Tim-3 (D) at days 8 and 14. (E–F) Representative contour plots depicting IFN-γ expressing CD8+ T cells in mice spleens and tumors following stimulation with PMA/ionomycin at day 8. (G–H) Quantitation of the percentage of TIL (G) and splenic (H) CD8+ T cells that expressed IFN-γ at days 8 and 14. Data represent the mean±SD. For (C), (D), (G) and (H), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001. IFN-γ, interferon-γ; IR, ionizing radiation.
Figure 5 Triple therapy attenuates coexpression of CD8+ T cell exhaustion markers and promotes CD8+ T cell effector function in mice tumors. (A–B) Representative contour plots depicting PD-1 and LAG-3 coexpression and PD-1 and Tim-3 coexpression on tumor-infiltrating lymphocyte (TIL) CD8+ T cells at day 8. (C–D) Quantitation of the percentage of TIL CD8+ T cells coexpressing PD-1 and LAG-3 (C), and PD-1 and Tim-3 (D) at days 8 and 14. (E–F) Representative contour plots depicting IFN-γ expressing CD8+ T cells in mice spleens and tumors following stimulation with PMA/ionomycin at day 8. (G–H) Quantitation of the percentage of TIL (G) and splenic (H) CD8+ T cells that expressed IFN-γ at days 8 and 14. Data represent the mean±SD. For (C), (D), (G) and (H), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. *p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001. IFN-γ, interferon-γ; IR, ionizing radiation.CC BY · PubMed Central
Figure 6 AZD6738 promotes radioimmunotherapy antitumor effect via activating cGAS/STING signaling pathway. (A) Several key proteins of cGAS/STING pathway were detected in Hepa 1–6 subcutaneous tumors from mice treated with radioimmunotherapy or triple therapy group. (B) Response of the Hepa 1–6 subcutaneous tumors to the indicated treatments. n=12 in each group. Data represent the mean±SEM. Statistical analysis was performed by using mixed-effects model, followed by Tukey’s multiple comparison test. ***p<0.0005. IR, ionizing radiation.
Figure 6 AZD6738 promotes radioimmunotherapy antitumor effect via activating cGAS/STING signaling pathway. (A) Several key proteins of cGAS/STING pathway were detected in Hepa 1–6 subcutaneous tumors from mice treated with radioimmunotherapy or triple therapy group. (B) Response of the Hepa 1–6 subcutaneous tumors to the indicated treatments. n=12 in each group. Data represent the mean±SEM. Statistical analysis was performed by using mixed-effects model, followed by Tukey’s multiple comparison test. ***p<0.0005. IR, ionizing radiation.CC BY · PubMed Central
Figure 7 Triple therapy promotes immune memory activation in mice tumors. (A) Representative contour plots depicting CD62L and CD44 expression in tumor-infiltrating lymphocyte (TIL) CD8+ T cells at day 8. (B–C) Quantitation of the percentage of TIL CD8+ T cell central memory (TCM, CD62L+CD44+) cells or effector memory (TEM, CD62L-CD44+) cells at days 8 and 14. (D) Mice tumors were re-challenged with Hepa 1–6 cells in the contralateral flank on the 20th day. Data represent the curve for the mean tumor volumes. Data represent the mean±SD. For (B) and (C), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. For (D), statistical analysis was performed using mixed-effects model, followed by Tukey’s multiple comparison test. *p<0.05; **p<0.005; ***p<0.0005. IR, ionizing radiation.
Figure 7 Triple therapy promotes immune memory activation in mice tumors. (A) Representative contour plots depicting CD62L and CD44 expression in tumor-infiltrating lymphocyte (TIL) CD8+ T cells at day 8. (B–C) Quantitation of the percentage of TIL CD8+ T cell central memory (TCM, CD62L+CD44+) cells or effector memory (TEM, CD62L-CD44+) cells at days 8 and 14. (D) Mice tumors were re-challenged with Hepa 1–6 cells in the contralateral flank on the 20th day. Data represent the curve for the mean tumor volumes. Data represent the mean±SD. For (B) and (C), statistical analysis was performed by using one-way analysis of variance with Tukey’s multiple comparisons test. For (D), statistical analysis was performed using mixed-effects model, followed by Tukey’s multiple comparison test. *p<0.05; **p<0.005; ***p<0.0005. IR, ionizing radiation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 241

Metadata

Authors
Sheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., Zhang, W., Sun, J., & Cao, C.
Affiliations
  • Nanfang Hospital (CN)
  • Department of Radiation Oncology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
  • Department of Stomatology, No 2 Hospital of Baoding, Baoding, Hebei, China
Corresponding author
Cao, Chuanhui
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-05
Volume
8
Issue
1
Pages
e000340
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3029836467
Cited by
228
References
40
Citations by year
2026: 24 · 2025: 40 · 2024: 36 · 2023: 42 · 2022: 49 · 2021: 31 · 2020: 5
FWCI
11.65
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81702390, 81903133)
  • Guangzhou Science and Technology Program key projects (201906010087)
  • Natural Science Foundation of Guangdong Province (2017A030310105, 2018A030313398)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
AZD6738, hepatocellular carcinoma, radioimmunotherapy, DNA repair inhibition, tumor immune microenvironment, immune checkpoint inhibitors, PD-L1 inhibitors, radiotherapy, cGAS-STING pathway, CD8+ T cells, regulatory T cells, T cell exhaustion, tumor-infiltrating lymphocytes, immunological memory, combination therapy, tumor recurrence
MeSH terms
Immune Checkpoint Inhibitors, Animals, Disease Models, Animal, Drug Synergism, Female, Carcinoma, Hepatocellular, Humans, Indoles, Liver Neoplasms, Morpholines, Pyrimidines, Sulfonamides, Sulfoxides, Lymphocytes, Tumor-Infiltrating, Radioimmunotherapy, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Tumor Microenvironment, Chemoradiotherapy, B7-H1 Antigen, Ataxia Telangiectasia Mutated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.